Whole Genome
Clinical Diagnostic Services
- Ending the diagnostic odyssey. Get fast, accurate diagnostics.
- Diagnosed by our US board certified geneticist
- Interactive diagnosis with the ordering physician
- Revolutionizing genomic medicine
- Ending the diagnostic odyssey. Get fast, accurate diagnostics.
- Diagnosed by our US board certified geneticist
- Interactive diagnosis with the ordering physician
- Revolutionizing genomic medicine
Variantyx offers a comprehensive set of advanced Whole Genome and Whole Exome products and services for diagnostic and research use. Our product portfolio ranges from time critical rare genetic disorder diagnosis to economical large research cohort projects.
Clinicians
Ending the diagnostic odyssey
Hospitals
Conduct in-house Whole-Genome diagnosis today
Labs
Clinical NGS interpretation and reporting solution
Whole Genome / Whole Exome Sequencing as the first line of diagnosis
The genomic diagnostics industry is currently at an inflection point, shifting from traditional technologies to Whole Genome / Whole Exome Next Generation Sequencing. Recent research shows that whole exome sequencing should be the first line of diagnosis.¹
Cutting edge genomic diagnosis
In the vanguard of this transition, Variantyx offers cutting edge solutions. These solutions include rapid whole genome based diagnostics, structural variant analysis, industry leading variant annotation databases and a proprietary variants database with 20+ million unique entries, providing a high diagnostic yield.
Leading industry standards and beyond
All samples are processed in CLIA-certified and CAP-accredited labs and are diagnosed by our US board certified geneticist in conjunction with the ordering physician. Our services are HIPAA compliant and fully insured. We have processed more than 1,000 Whole Genome / Whole Exome cases for hospitals and clinicians worldwide.
Meet us at Booth #464
Meet us at
¹"WES resulted in diagnostically useful outcomes in 29.4% of patients. The entire traditional diagnostic trajectory average cost was $16,409 per patient, substantially higher than the $3,972 trio-WES cost. WES resulted in average cost savings of $3,547 for genetic and metabolic investigations in diagnosed patients and $1,727 for genetic investigations in undiagnosed patients."
Source: Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability Glen R. Monroe, et. al. Genetics in Medicine (2016)